Device Trial Radar · NCT06306573
CardioMEMS HF System Real-World Evidence Post-Approval Study
Last checked: Nov 20, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
2,500
Planned (sponsor's estimate)
Start
Dec 15, 2022
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Mar 12, 2024
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
The purpose of this post-approval study (PAS) is to evaluate the long-term safety and effectiveness of the CardioMEMS™ HF System using real-world evidence (RWE) methods.
Conditions
- Heart Failure NYHA Class II
- Heart Failure NYHA Class III
Interventions
CardioMEMS HF SystemDevice
The CardioMEMS HF System provides pulmonary artery (PA) hemodynamic data to monitor and manage HF subjects. The CardioMEMS HF System measures PA pressure which clinicians use to initiate or modify HF treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Two-Year Survival in NYHA Class II subjects without a history of severe renal diseaseTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Abbott Medical
Atlanta, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.